MedTrace Logo

Hesperidin and Bone Health in Postmenopausal Women

NCT01881204 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-05-17

No results posted yet for this study

Summary

The primary objective of this clinical trial is to test hesperidin with and without CALCILOCK® for bone resorption suppressing effect in postmenopausal women. The secondary objective is the comparison between 41Ca technology and classical biomarker to evaluate bone resorption.

Conditions

  • Osteoporosis, Postmenopausal

Interventions

DIETARY_SUPPLEMENT

Hesperidin and Calcilock

Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).

DIETARY_SUPPLEMENT

Hesperidin

Hesperidin (552mg) will be administered in the form of cookies (biscuit).

DIETARY_SUPPLEMENT

Control

Cookies without Hesperidin or Calcilock added.

Sponsors & Collaborators

  • Nestec Ltd.

    collaborator INDUSTRY

  • Purdue University

    lead OTHER

Principal Investigators

  • Connie M Weaver, Ph.D. · Purdue University

  • Berdine R Martin, PhD · Purdue University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01881204 on ClinicalTrials.gov